Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals.

The most electronegative constituents of human plasma LDL (i.e., L5) and VLDL (i.e., V5) are highly atherogenic. We determined whether the combined electronegativity of L5 and V5 (i.e., L5 + V5) plays a role in coronary heart disease (CHD). In 33 asymptomatic individuals (ages 32-64), 10-year hard CHD risk correlated with age (r = 0.42, = 0.01). However, in age-adjusted analyses, 10-year hard CHD risk correlated with L5 + V5 plasma concentration (r = 0.43, = 0.01) but not age ( = 0.74). L5 + V5 plasma concentration was significantly greater in the group with high CHD risk (39.4 ± 22.0 mg/dL; = 17) than in the group with low CHD risk (16.9 ± 14.8 mg/dL; = 16; = 0.01). In cultured human aortic endothelial cells, L5 + V5 treatment induced significantly more senescence-associated-β-Gal activity than did equal concentrations of L1 + V1 ( = 4, < 0.001). To evaluate the in vivo relevance of these findings, we fed ApoE and wild-type mice with a high-fat diet and found that plasma LDL, VLDL, and LDL + VLDL from ApoE mice exhibited significantly greater electrophoretic mobility than did wild-type counterparts ( = 6, < 0.01). The increased electronegativity of LDL and VLDL in ApoE mice was accompanied by increased aortic lipid accumulation and cellular senescence ( = 6, < 0.05). Clinical trials are warranted to test the predictive value of L5 + V5 concentration in patients with CHD.